Factors Influencing anti-Xa assays: A Multicenter Prospective Study in Critically Ill and Noncritically Ill Patients Receiving Unfractionated Heparin.

Dominique LasneMarie Toussaint-HacquardCéline DelassasseigneAnne BautersClaire FlaujacPhilippe SavardChristine MoutonEmmanuel De MaistreAlain StepanianValérie EschwègeMaxime DelrueJean-Louis GeorgesAntoine GrosAlexandre MansourGuillaume LeroyRomain JouffroyMatthieu MatteiAntoine BeurtonAdeline PontisMarie NeuwirthFabienne Nedelec-GacThomas LecompteEmmanuel CurisVirginie SiguretIsabelle Gouin-Thibault

Published in: Thrombosis and haemostasis (2023)

The variability of anti-Xa levels with a great overestimation of the values, using a reagent containing DS, can lead to different treatment decisions, especially after heparin neutralization by protamine. Clinical consequences of these differences remain to be demonstrated.

Keyphrases

venous thromboembolism
growth factor
cross sectional
clinical trial
double blind
combination therapy